



Introduction

- Inflammatory bowel disease (IBD) is characterized by chronic, relapsing periods of intestinal inflammation with an unpredictable clinical course¹.
- IBD flares may impact patients' quality of life, require frequent admissions, and contribute to missed work and impact work disability².
- Race and gender disparities have been shown to impact IBD's course.

Study Aim

This study focuses on elucidating differences in work disability by race and gender in IBD patients.


A cross-sectional study at our tertiary referral center enrolled IBD patients on the day of their colonoscopy. Patients received surveys containing demographic, socioeconomic, quality of life, and work disability questionnaire (the WPAI tool).

Methods

After scope completion, scores for endoscopic disease severity were recorded. Via a retrospective approach, charts were reviewed for long term outcomes: admissions, ER visits, steroid use, and surgeries one year post enrollment.

Differences in Work Disability by Race and Gender in Patients with Inflammatory Bowel Disease

<u>Deannys Batista MD¹, Maya Krasnow MD¹, John T. Menchaca MD¹, Chunsu Jiang MD¹, Tanvi Dhere MD², Heba Iskandar, MD²</u>



1. Emory University School of Medicine, Atlanta, GA, 2. Emory University Division of Digestive Diseases, Atlanta, GA

p-value	Non-White (n, %)	White (n, %)	p-value
.204	9 (100)	22 (95.7)	1
.459	0 (0)	1 (4.3)	1
1	21 (100)	56 (94.9)	.563
.618	0 (0)	3 (5.1)	.563
.050	21 (100)	53 (89.8)	.332
.099	0 (0)	6 (10.2)	.332
.110	15 (71.4)	38 (64.4)	.604
.015	4 (19)	19 (32.2)	.400
.603	1 (4.8)	2 (3.4)	1
.477	1 (4.8)	0 (0)	.262

	Age			
	HBI			
	SES-CD			
	N (%) or mean ± standard de *p<0.05 Abbreviations: OR=Odds rat Crohn's Disease			
(p= vis	Data obtained via Work Prod nder: Females ha 0.05) than male its and admission nificant.			
Но	<u>e:</u> We found no e wever, non-white npared to whites			
tho	<u>Type:</u> Crohn's pa se with UC (10;1 ease, was associa			
	nderstanding le perative for e			
	ur study sugge ce differences			
	dditional studi dings and to h			
1. Ballou S, Hirsch W, Singh P, Rangan Emergency department utilisation for inf 10.1111/apt.14551. Epub 2018 Feb 7. Pl				
2. Leso V, Gervetti P, Macrini MC, Russo				



Results

	No Work Absences	>1 Work Absence	OR (95% CI)
Male Female	35 (92.1) 34 (82.9)	3 (7.9) 7 (17.1)	2.4 (0.6-10.1)
White Non-White	50 (92.6) 17 (73.9)	4 (7.4) 6 (26.1)	4.4 (1.1-17.5)*
CD UC	33 (78.6) 37 (97.4)	9 (21.4) 1 (2.6)	10.1 (1.2-84)*
	41.8 ± 14.6	40.0 ± 14.4	1.0 (0.9-1.0)
	4.5 ± 4.3	7.0 ± 4.7	1.1 (1.0-1.3)
	5.9 ± 6.0	14.6 ± 5.7	1.2 (1.1-1.4)*

tio; CD= Crohn's Disease; UC= Ulcerative Colitis; HBI= Harvey-Bradshaw Index; SES-CD= Simple Endoscopic Score for

and Activity Impairment (WPAI) questionnaire, a validated tool of work impairment measure

nad significantly more steroid use events (p=0.015) and surgeries es, but no differences in work impairment. However, differences in ER ons between genders one year following enrollment were not

difference in long term outcomes between whites and non-whites. e patients had 4 times the odds of having work missed due to health es (OR 4.4; 1.1-17.5).

patients were 10 times more likely to miss work due to health than .2-84.0). In CD patients, endoscopic disease severity, but not clinical iated with missed work.

Summary and Conclusions

long term outcomes, health, gender, and race disparities is effective management of IBD patients.

ests gender differences in long term outcomes of IBD, and in missed work.

lies are needed to further characterize the reasons for these help improve patient's work and activity impairment.

References

V, Nee J, Iturrino J, Sommers T, Zubiago J, Sengupta N, Bollom A, Jones M, Moss AC, Flier SN, Cheifetz AS, Lembo A. ammatory bowel disease in the United States from 2006 to 2014. Aliment Pharmacol Ther. 2018 Apr;47(7):913-921. doi: PMID: 29411411; PMCID: PMC5927595.

Russo F, lavicoli I. Inflammatory bowel diseases and work disability: a systematic review of predictive factors. Eur Rev Med Pharmacol Sci. 2021 Jan;25(1):165-181. doi: 10.26355/eurrev_202101_24382. PMID: 33506905.